Sulconazole nitrate is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, as well as for tinea versicolor. Its effectiveness has not been established in tinea pedis (athlete’s foot). Symptomatic relief is usually observed within a few days of starting treatment, while clinical improvement generally occurs within one week.

Sulconazole nitrate is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, including Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis. It also inhibits Malassezia furfur, the organism responsible for tinea versicolor, as well as certain Gram-positive bacteria. A maximization test with sulconazole nitrate solution showed no evidence of irritation or contact sensitization.

A small amount of the solution should be gently massaged into the affected and surrounding skin areas once or twice daily. Symptomatic relief usually occurs within a few days after starting Sulconazole nitrate, and clinical improvement usually occurs within one week. To reduce the possibility of recurrence, tinea cruris, tinea corporis, and tinea versicolor should be treated for 3 weeks. If significant clinical improvement is not seen after 4 weeks of treatment, an alternate diagnosis should be considered.

Pediatric Use: Safety and effectiveness in children have not been established.

Geriatric Use: Clinical studies of Sulconazole Nitrate, did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients.

Sulconazole nitrate is contraindicated in patients with a known history of hypersensitivity to any of its ingredients.

In controlled clinical trials involving 370 patients, no systemic effects were observed. Only rare cutaneous adverse reactions were reported. Approximately 1% of patients experienced itching and about 1% reported burning or stinging sensations. These symptoms were generally mild and did not interfere with treatment.

US FDA Pregnancy Category C. Animal studies showed embryotoxicity in rats at doses approximately 125 times the human dose (mg/kg basis), resulting in prolonged gestation, dystocia, and perinatal deaths likely due to labor complications. However, no teratogenic effects were observed in rats or rabbits at oral doses up to 50 mg/kg/day.

There are no controlled studies in human pregnancy. It is unknown whether the drug is excreted in human or animal breast milk.

For external use only. Avoid contact with eyes. If irritation occurs, discontinue use and initiate appropriate therapy. Patients should be advised to use the medication exactly as prescribed and only for external application.

Long-term carcinogenicity studies have not been performed. In vitro studies have shown no mutagenic activity.

Topical Antifungal preparations

Store below 30°C. Keep away from light and moisture. Keep out of reach of children.